Neothetics, Inc.’s Stock Tumbles Following “Unambiguous” Negative LIPO-202 Results

Neothetics, Inc.’s LIPO-202 for the reduction of submental subcutaneous fat failed to demonstrate improvement on any efficacy measurements or separation from placebo in a Phase 2 proof-of-concept trial.
Neothetics Inc. shares dropped 66% in premarket trade Monday on news of negative results for its fat-reduction drug. 
“We are disappointed in these results, which are unambiguous,” said Dr. Dan Piacquadio, head of Neothetics’ Development Committee, in a news release.
This same drug also failed to past muster in a December 2015 study that looked at its use in reducing subcutaneous fat in the abdominal area.
LIPO-202-CL-31 was a multi-center, randomized, double-blind, placebo-controlled Phase 2 proof of concept trial to evaluate the safety and efficacy of two doses of LIPO-202 versus placebo for the reduction of submental bulging due to subcutaneous fat.  The trial enrolled 162 subjects at 12 sites across the United States.  Subjects were randomized 1:1:1 and received up to either 0.3 mcg, or 3.0 mcg dose of LIPO-202, or placebo.  Subjects received up to 30 subcutaneous injections of LIPO-202 or placebo once a week for eight weeks and follow up visits to assess safety and efficacy occurred one week and four weeks post the last treatment.
Read more at Aesthetics Wire >>